Another recent meta-analysis confirmed that SGLT2 inhibitors were associated with a reduced risk of COPD compared with placebo (RR 0.77; 95% CI: 0.62–0.96), regardless of whether they were used at high or low doses [90]. This evidence concerns the gene SLC5A2 and chronic obstructive pulmonary disease.